DB01427ApprovedWithdrawnSmall molecule
Amrinone is a positive inotropic agent and phosphodiesterase inhibitor used in the management of treatment of congestive heart failure.
- Mechanism
- Curator reviewed
Amrinone is a phosphodiesterase inhibitor (PDE3), resulting in increased cAMP and cGMP which leads to an increase in the calcium influx like that caused by beta-agonists resulting in increased inotropic effect.
- Primary indication
- Used in the treatment of congestive heart failure.Curator reviewed
- Formula / weight
- C10H9N3O · 187.198 g/mol (avg)
- First approval
- Canada, 1984 · United States, 2000
- Also known as
- Inamrinone
- Code names
- C01CE01 · WIN-40680
Resolves to
Clinical / RWD
Structure
InChIKey
RNLQIBCLLYYYFJ-UHFFFAOYSA-NSMILESNC1=CC(=CNC1=O)C1=CC=NC=C1What you can answer from here — as of September 23, 2026
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Amrinone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account